GPR40 Agonist and SGLT2 Inhibitor Combination for Type 2 Diabetes
Solution Overview
Problem
Current treatments for Type 2 diabetes often require multiple agents with side effects, and there is a need for a therapeutic approach that effectively manages glucose levels without risking hypoglycemia and with a favorable safety profile.
Innovation Solution
A pharmaceutical composition comprising a GPR40 agonist and an SGLT2 inhibitor, specifically a compound of Formula (I), which enhances glucose-dependent insulin secretion and promotes urinary glucose excretion, thereby treating Type 2 diabetes and related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple anti-diabetic agents are used to effectively manage glucose levels, then glucose control is improved, but the risk of hypoglycemia and side effects increases
Solution Approach 1:
The patent segments the anti-diabetic treatment into two distinct mechanisms: GPR40 agonism for glucose-dependent insulin secretion enhancement and SGLT2 inhibition for urinary glucose excretion. This segmentation allows each component to address glucose control through different pathways, reducing the cumulative hypoglycemia risk while maintaining effective glucose management
Solution Approach 2:
The patent changes the therapeutic parameter from non-glucose-dependent insulin secretion (sulfonylureas) to glucose-dependent insulin secretion (GPR40 agonists). This parameter change ensures that insulin secretion is tightly coupled to glucose levels, eliminating hypoglycemia risk while maintaining glucose control efficacy
2Reliability
If sulfonylureas are used to enhance insulin secretion, then glucose control is improved, but the risk of hypoglycemia increases due to glucose-independent mechanism
Solution Approach 1:
The patent inverts the mechanism of action from glucose-independent insulin secretion (sulfonylureas) to glucose-dependent insulin secretion (GPR40 agonists). By making insulin secretion dependent on glucose levels through GPR40 activation, the treatment achieves glucose control while inherently preventing hypoglycemia
Solution Approach 2:
The GPR40 agonist mechanism provides glucose-level feedback control for insulin secretion. When glucose levels rise, GPR40 is activated and insulin secretion increases; when glucose levels fall, GPR40 activation decreases and insulin secretion reduces. This feedback mechanism automatically prevents hypoglycemia
3Reliability
If glitazones are used as insulin sensitizers, then insulin action is enhanced, but weight gain and edema occur as side effects
Solution Approach 1:
The patent extracts the insulin sensitizing effect from PPAR-γ activation (glitazones) and replaces it with dual mechanisms: GPR40 agonism for insulin secretion enhancement and SGLT2 inhibition for urinary glucose excretion. This extraction eliminates the weight gain and edema side effects associated with glitazones while maintaining insulin sensitivity benefits
Solution Approach 2:
The patent copies the beneficial effect of enhanced insulin action through alternative mechanisms. Instead of using PPAR-γ activation, it achieves similar metabolic improvement through GPR40-mediated insulin secretion and SGLT2-mediated glucose excretion, producing the same clinical benefit without the harmful side effects
Data Source
AI summary
Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows:wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.